000			03423nam a22004095i 4500
988			_aEbook_one2one
999			_c84875 _d84875 _x1
001			84875
003			ES-MaUEC
005			20240611040140.0
007			cr nn 008mamaa
008			160317s2016 gw | s |||| 0|eng d
020			_a9783319229096
040			_aES-MaUEC
050		4	_aRC270.3.T84 _bN58 2016 EB
082	0	4	_a614.5999
245	1	0	_aNovel Biomarkers in the Continuum of Breast Cancer _cedited by Vered Stearns
250			_a1st ed.
264		1	_aCham _bSpringer International Publishing _c2016
300			_a1 recurso en línea (XIX, 279 páginas) _b34 ilustraciones, 4 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aAdvances in Experimental Medicine and Biology _x0065-2598 _v882
505	0		_a1 Genomic Biomarkers for Cancer Risk -- 2 Epigenetic Biomarkers of Breast Cancer Risk: Across the Breast Cancer Prevention Continuum -- 3 Incorporating Biomarkers in Studies of Chemoprevention -- 4 Breast Molecular Profiling and Radiotherapy Considerations -- 5 Prognostic and Predictive Biomarkers of Endocrine Responsiveness For Estrogen Receptor Positive Breast Cancer -- 6 Biomarkers for predicting response to Anti-HER2 Agents -- 7 Intratumor Heterogeneity in Breast Cancer -- 8 Intratumor Heterogeneity in Breast Cancer -- 9 Pharmacogenetic Predictors of Response -- 10 Metabolomics in Breast Cancer: Current Status and Perspectives -- 11 Circulating Tumor Cells -- 12 Circulating Plasma Tumor DNA.
520			_aThis volume provides a comprehensive review of established and novel biomarkers across the continuum of breast cancer. The volume covers topics related to breast cancer risk and prevention, prediction of response to today�s standard therapies, and markers capable of influencing treatment decisions in the near future. Chapter authors combine their wide-ranging expertise to review the current status of the biomarker and to offer their individual perspectives on how biomarkers may be used in future treatments and research. Breast cancer continues to be the most common malignancy diagnosed in women in the Western world. While there are multiple treatment approaches for breast cancer, today more than ever we recognize that each tumor is unique. The challenge ahead is to consider how to best use validated and novel biomarkers to select the most appropriate treatment for individual patients.
650		7	_aMarcadores tumorales _2embne _9144360
650		7	_aGenética humana _2embne _9140562
700	1		_aStearns, Vered. _eeditor literario _997408 _0Local _0http://id.loc.gov/authorities/names/nb2016008516 _1http://viaf.org/viaf/16146332926818732468
710	2		_aSpringerLink (Online service) _0Local _0http://id.loc.gov/authorities/names/no2005046756 _1http://viaf.org/viaf/148105729 _9106996
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-22909-6 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9783319229096
907			_a.b12941530 _b10-10-17 _c21-11-16
942			_2lcc _cLE
945			_aEBOOK EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11613002 _z30-06-17
988	0	0	_aEBOOK, EBSPRINGER, GOBI_sep2018
998			_aSI _a_alco _a_vill _b10/2018 _cm _dz _ef _feng _ggw _h0